HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice.

Abstract
Incretin hormones, including glucagon-like peptide-1 (GLP-1), a target for diabetes mellitus (DM) treatment, are associated with cardioprotection. As dipeptidyl-peptidase IV (DPP-IV) inhibition increases plasma GLP-1 levels in vivo, we investigated the cardioprotective effects of the DPP-IV inhibitor vildagliptin in a murine heart failure (HF) model. We induced transverse aortic constriction (TAC) in C57BL/6J mice, simulating pressure-overloaded cardiac hypertrophy and HF. TAC or sham-operated mice were treated with or without vildagliptin. An intraperitoneal glucose tolerance test revealed that blood glucose levels were higher in the TAC than in sham-operated mice, and these levels improved with vildagliptin administration in both groups. Vildagliptin increased plasma GLP-1 levels in the TAC mice and ameliorated TAC-induced left ventricular enlargement and dysfunction. Vildagliptin palliated both myocardial apoptosis and fibrosis in TAC mice, demonstrated by histological, gene and protein expression analyses, and improved survival rate on day 28 (TAC with vildagliptin, 67.5%; TAC without vildagliptin, 41.5%; P < 0.05). Vildagliptin improved cardiac dysfunction and overall survival in the TAC mice, both by improving impaired glucose tolerance and by increasing GLP-1 levels. DPP-IV inhibitors represent a candidate treatment for HF patients with or without DM.
AuthorsAyako Takahashi, Masanori Asakura, Shin Ito, Kyung-Duk Min, Kazuhiro Shindo, Yi Yan, Yulin Liao, Satoru Yamazaki, Shoji Sanada, Yoshihiro Asano, Hatsue Ishibashi-Ueda, Seiji Takashima, Tetsuo Minamino, Hiroshi Asanuma, Naoki Mochizuki, Masafumi Kitakaze
JournalAmerican journal of physiology. Heart and circulatory physiology (Am J Physiol Heart Circ Physiol) Vol. 304 Issue 10 Pg. H1361-9 (May 15 2013) ISSN: 1522-1539 [Electronic] United States
PMID23504176 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Dipeptidyl-Peptidase IV Inhibitors
  • Nitriles
  • Pyrrolidines
  • Glucagon-Like Peptide 1
  • Vildagliptin
  • Adamantane
Topics
  • Adamantane (analogs & derivatives, pharmacology)
  • Animals
  • Apoptosis (drug effects)
  • Blood Pressure (drug effects, physiology)
  • Blotting, Western
  • Dipeptidyl-Peptidase IV Inhibitors (pharmacology)
  • Electrocardiography (drug effects)
  • Enzyme-Linked Immunosorbent Assay
  • Fibrosis
  • Glucagon-Like Peptide 1 (metabolism)
  • Glucose Tolerance Test
  • Heart Failure (drug therapy, physiopathology)
  • Heart Rate (drug effects)
  • Hemodynamics (drug effects)
  • Immunohistochemistry
  • In Situ Nick-End Labeling
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Nitriles (pharmacology)
  • Organ Size (drug effects)
  • Pyrrolidines (pharmacology)
  • Real-Time Polymerase Chain Reaction
  • Survival
  • Vildagliptin

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: